All News

Testosterone replacement therapy (TRT) in hypogonadal men does not appear to increase the risk for prostate cancer, according to an evaluation of 224 men with an indication for prostate biopsy, providing further evidence that TRT need not be avoided in this patient group.

A study from the UCLA Ronald Reagan Medical Center appears to once again prove that time is money. The study’s findings indicate that up to $15 million could be saved annually by referring patients who are candidates for robot-assisted radical prostatectomy to surgeons and surgical centers with optimal operating times.

Astellas Pharma Inc. and Medivation Inc. have submitted a supplemental new drug application to the FDA seeking approval of enzalutamide (XTANDI) capsules for the treatment of men with metastatic castration-resistant prostate cancer who have not received chemotherapy.

J. Stuart Wolf, MD, will serve as the first chair of the AUA’s newly created Science & Quality (S&Q) Council, the association announced.

The Centers for Medicare & Medicaid Services has issued two new codes that describe the UroLift implant procedure for the treatment of enlarged prostate in the April 2014 Update of the Hospital Outpatient Prospective Payment System (OPPS).

Patients are demanding transparency and access to their health information, and recent initiatives from the government and private insurers are addressing these demands.

Federal estate tax exemption portability represents a huge potential benefit for many estates that should not be overlooked.

A new generation of prostate cancer biomarkers promises to alter the way in which urologists make clinical management decisions.

In the lawsuit, the urologist contended the circumcision was properly performed and the patient’s curvature was due to a previously asymptomatic Peyronie’s condition, which was exacerbated after the circumcision procedure.

Earl Cheng, MD, has been appointed division head of urology at Ann & Robert H. Lurie Children’s Hospital of Chicago, after serving as the interim division head since July 2013.

The U.S. Preventive Services Task Force recommendation against routine prostate cancer screening has resulted in a decrease in the number of PSA-based screenings ordered by physicians, with the greatest decline seen among urologists, according to findings of recently published study that one leading prostate cancer expert says raises more questions than it answers.

Relying on blood test results alone is insufficient for diagnosing hypogonadism, according to a recent study.

One of the AUA’s top legislative priorities for 2014-opposing or deferring implementation of the International Classification of Diseases-10th revision (ICD-10)-appears to be in danger.

Levels of bisphenol A in men’s urine could be a marker of prostate cancer, and male exposure to other environmental chemicals used in the manufacture of plastics appear to negatively impact time to pregnancy, two separate studies have found.

Learn more about MRI-guided biopsy with these videos.

The FDA has approved testosterone undecanoate (AVEED) injection for treatment of men with hypogonadism.

Radical prostatectomy is associated with a substantial long-term reduction in mortality in men with localized cancer, especially in younger patients, according to newly published data from one of the few randomized trials to directly address the surgery-versus-surveillance issue.

A diet typically used to lower blood pressure may reduce the risk of kidney stone development, according to a small, recently published study.

Prostate cancer patients who undergo robot-assisted radical prostatectomy have fewer positive surgical margins and less need for additional cancer treatments such as hormone or radiation therapy than patients undergoing open surgery, an observational study from UCLA’s Jonsson Comprehensive Cancer Center has found.

In the first installment of a two-part series, Dr. Henry Rosevear examines how America established its current health insurance system, both private and public.

Montefiore Medical Center and Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, have named Mark Schoenberg, MD, professor and university chair of the department of urology. He will assume his new position in April 2014.

Most prostate cancer experts aren’t ready to call the incorporation of MRI fusion into prostate biopsies the gold standard in prostate cancer imaging and diagnosis. But they envision a day when it will be.

In clinical practice, experts told Urology Times, men who may benefit from MR-guided prostate biopsy generally fall into one of four scenarios.

Urology Times is pleased to welcome Henry Rosevear, MD, to the publication’s Clinical Practice Board.

Drugs and devices in the pipeline from VIVUS, Auxilium Pharmaceuticals, OncoGenex Pharmaceuticals, Veloxis Pharmaceuticals, OPKO Health, and Oxthera AB.

Urologists say that while the AUA's recommendations are good guidelines, it's important to take the individual patient's characteristics into consideration.

The makers of the Decipher and ConfirmMDx prostate cancer tests have announced separate agreements that will expand insurance coverage for the two tests.